KIF20A

Across TCGA pan-cancer cohorts, KIF20A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIF20A data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher KIF20A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIF20A expression acts as an unfavorable survival marker.

LUSC, STAD, and BLCA are the cancer types where KIF20A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.146	0.777	<.001	24	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KIF20A–LUSC (OS)

Open the LUSC breakdown →